These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 12571855)

  • 21. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
    Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus.
    Lee HS; Chung YH; Kim TG; Kim TH; Jun JB; Jung S; Bae SC; Yoo DH
    Rheumatology (Oxford); 2003 Dec; 42(12):1501-7. PubMed ID: 12867584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK; Levy R
    J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD; Patey S; Brogan PA; Hasson N; Pilkington C; Woo P; Tullus K
    Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rituximab in systemic lupus erythematosus. Part I. Theoretical basis].
    Kardynał A; Rudnicka L
    Pol Merkur Lekarski; 2010 Aug; 29(170):131-4. PubMed ID: 20842829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
    Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
    Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
    Cambridge G; Leandro MJ; Teodorescu M; Manson J; Rahman A; Isenberg DA; Edwards JC
    Arthritis Rheum; 2006 Nov; 54(11):3612-22. PubMed ID: 17075806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
    Sutter JA; Kwan-Morley J; Dunham J; Du YZ; Kamoun M; Albert D; Eisenberg RA; Luning Prak ET
    Clin Immunol; 2008 Mar; 126(3):282-90. PubMed ID: 18226586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.
    Tanaka Y; Suzuki Y; Tsuge T; Kanamaru Y; Horikoshi S; Monteiro RC; Tomino Y
    Nephrol Dial Transplant; 2005 Nov; 20(11):2439-45. PubMed ID: 16221721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
    Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
    J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab: a promising therapy in systemic lupus erythematosus.
    Thatayatikom A; White AJ
    Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
    Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
    Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of rituximab in patients with systemic lupus erythematosus: an update.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
    Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.
    Vallerskog T; Gunnarsson I; Widhe M; Risselada A; Klareskog L; van Vollenhoven R; Malmström V; Trollmo C
    Clin Immunol; 2007 Jan; 122(1):62-74. PubMed ID: 17046329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
    Forero-Torres A; de Vos S; Pohlman BL; Pashkevich M; Cronier DM; Dang NH; Carpenter SP; Allan BW; Nelson JG; Slapak CA; Smith MR; Link BK; Wooldridge JE; Ganjoo KN
    Clin Cancer Res; 2012 Mar; 18(5):1395-403. PubMed ID: 22223529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.